Technologies and information in post-genome sequencing era are being applied to create unique contributions to medical treatment.

The entire sequences of the human genome have been almost completely determined, and scientists have determined the number of genes is about 30,000. Gene analysis information is expected to generate major contributions to the foundations and applications of the life sciences. The Clinical Genomics Dept. has adopted this technology and information in order to provide state-of-the-art analysis for use in medical treatment.

BML provides gene analysis services using state-of-the-art technology.

The Clinical Genomics Dept. aims at practical use of order-made medicine such as analysis for single nucleotide polymorphisms (SNPs) of genes coding for drug metabolizing enzymes and target proteins responsible for anti-cancer drugs, mainly using the Invader Technology standards developed by Third Wave Technologies, Inc., a U.S.-based bio-tech venture business for the analysis of SNPs. BML will continue to apply this state-of-the-art technology in order to provide molecular biology tests such as gene expression analysis and testing for genes that cause susceptibility to infectious diseases. By uniting the above-mentioned technologies with accuracy control management system established through clinical testing, a national medical care network, and IT technologies used in projects involving electronic medical charts, BML is ready to embark on the creation of additional services in this new field of medicine.